,38 In the KEYNOTE-189, it was found that patients with KRAS G12C-positive NSCLC had similar ORR compared with all patients with unspecified KRAS-mutated NSCLC after treatment with pembrolizumab plus chemotherapy.39 The gene discussed is KRAS; the disease is non-small cell lung carcinoma.